Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life

MV18Months

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

2016-10-01

2020-05-01

2021-05-01

Completed

3812

Inclusion Criteria: * Children need to have received the third dose of inactivated vaccines (Penta, PCV13 and IPV) before measles vaccination. Exclusion Criteria: * Having severe malformations that impairs their health * Having received a second dose of measles vaccine * Severely ill (requiring hospitalization) upon clinical examination

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 3812, 'type': 'ACTUAL'}}

2024-01-19